Pharmacokinetics and Safety of Ticarcillin-clavulanate in Infants

NCT01229046 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2012-11-14

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability and PK of ticarcillin-clavulanate in infants \<91 days of age with suspected systemic infection.

Conditions

Interventions

DRUG

Ticarcillin-clavulanic acid

5 doses of IV ticarcillin-clavulanate infants \< 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8

Sponsors & Collaborators

  • Phillip Brian Smith

    lead OTHER

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
90 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01229046 on ClinicalTrials.gov